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Abstract
Background Measuring liver stiffness is becoming more
popular as a non-invasive tool for assessing liver fibrosis.
Aim To assess the effect of severe hepatitis B flare on
liver stiffness and determine factors that correlate with
liver stiffness measurements.
Methods Twenty-nine patients with severe hepatitis B
flare (ALT [ 10 9 upper limit of normal) were followed
up for 1 year. Serial transient elastography was performed
at the time of flare, 3–6, and 12 months after flare.
Results At the time of flare, the median liver stiffness was
16.8 kPa, with no patients having normal liver stiffness
(\6 kPa). There was a significant decrease in liver stiffness
from baseline to 3–6 months (16.8 vs. 7.9 kPa, respec-
tively, P \ 0.001), and a further smaller decline from 3–6
to 12 months (7.9 vs. 6.9 kPa, respectively, P = 0.039).
By 12 months, 10 (34%) had normalized their liver stiff-
ness. Baseline parameters which correlated with liver
stiffness include bilirubin, ALT, albumin, prothrombin
time and platelet levels (all P \ 0.05).
Conclusion Liver stiffness was increased in patients with
severe hepatitis B flares, with return to near normal levels
by 6 months. Transient elastography for proper assessment
of liver fibrosis should be performed at least 6 months after
flare.
Keywords Hepatitis B  Liver stiffness 
Transient elastography  Fibroscan  Flare  Fibrosis
Background
Recently, there has been increasing interest in the devel-
opment of non-invasive assessment of liver fibrosis. The
current ‘‘gold’’ standard for assessment of liver fibrosis
remains the liver biopsy. However, liver biopsy is an
invasive procedure associated with both patient morbidity
and, less commonly, mortality. In Asia, where chronic
hepatitis B is endemic, there is a constant need for physi-
cians to evaluate the severity of underlying fibrosis, so that
treatment to retard disease progression can be started for
eligible patients. Likewise, it is important to identify
patients with underlying cirrhosis to screen for varices and
hepatocellular carcinoma. Because of the high rate of non-
acceptance of liver biopsy in Asian patients, they are rarely
performed. Therefore, there is a need for a more acceptable
method of assessment of liver fibrosis.
Liver stiffness measurement using transient elastogra-
phy has become available as a non-invasive assessment of
liver fibrosis. Transient elastography determines liver
elasticity by measuring the velocity of a low-frequency
shear wave passing through the liver. Previous studies
have shown good correlation between liver stiffness and
liver fibrosis, with a AUROC of greater than 0.90 for
METAVIR stage 3 fibrosis or greater in patients with
hepatitis C, hepatitis C co-infected with human immu-
nodeficiency virus, chronic biliary disease, and other liver
diseases [1–5]. The diagnostic accuracy of transient
elastography for liver fibrosis is supported by a recently
published meta-analysis [6]. Although an earlier study
showed no correlation between disease activity and liver
stiffness, more recent studies have shown that liver
stiffness appears to be affected by underlying inflamma-
tion, as in patients with acute hepatitis flares [7, 8]. In the
present study, we aim to determine the effect of severe
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flare of hepatitis B on liver stiffness measurements over a
12-month period.
Patients and methods
This was a prospective study. All chronic hepatitis B
patients, defined by hepatitis B surface antigen (HBsAg)
positive for more than 6 months, with hepatitis B flare of
ALT greater than 10 times upper limit of normal (ULN),
and admitted to Queen Mary Hospital, Hong Kong,
between the period May 2006 and August 2007, were
included. All patients had HBV DNA levels [105 copies/
mL. Acute hepatitis A and E were excluded by serological
testing. Drug-induced hepatitis was excluded by careful
history taking. None of the patients included had under-
lying significant alcohol intake as defined by a daily intake
of [20 g/day. All patients gave informed consent prior to
the testing for liver stiffness measurements. Patient
demographics and laboratory parameters were recorded at
the time of liver stiffness measurement, including age, sex,
liver biochemistry, HBsAg, hepatitis B e-antigen (HBeAg),
antibody to HBeAg (anti-HBe), and serum HBV DNA
levels. HBV DNA was measured using the COBAS Taq-
man HBV DNA Assay (Roche Diagnostics, Branchburg,
NJ), with a lower detection limit of 60 copies/mL.
Liver stiffness measurement
Liver stiffness measurement was performed using the Fi-
broscan (EchoSens, Paris, France). This procedure has
been well described previously [2]. Only patients with at
least ten valid measurements and a success rate of over 60%
were included. Liver stiffness scores were expressed in units
of kilopascals (kPa). This was performed in all patients at the
time of admission, 3–6, and 12 months after the time of flare.
A subgroup also had liver stiffness determined at 4 weeks
after flare. We adopted the value of\6.0 kPa as normal liver
stiffness, as defined by a previous study [9].
Liver histology
Five patients underwent liver biopsy during their hepatitis B
flare. Three patients were admitted for hepatitis B flare outside
the recruitment period (with the same inclusion and exclusion
criteria as listed). The necroinflammatory scores and degree
of fibrosis were assessed according to the modified hepatic
activity index grading and staging system [10, 11].
Statistical analysis
All statistical analyses were performed using the SPSS
version 14.0 (SPSS Inc, Chicago, IL). Chi-square test was
used for categorical variables, and Fisher’s exact test when
appropriate. Continuous variables with skewed distribution
were analyzed using Mann–Whitney test. Paired related
data were analyzed using the Wilcoxon paired test. Cor-
relation between liver stiffness and liver biochemistry was
performed using Spearman’s bivariate correlation. A
P value of \0.05 was considered statistically significant.
Results
A total of 38 patients were recruited during the study
period. Five patients were excluded due to inadequate
follow-up, and further four patients were excluded due to a
success rate of\60% in any one of their scans at the three
different time points. Twenty-nine patients were included
in the final analysis. One patient had documented evidence
of fatty liver disease on ultrasonography. The patient’s
demographic, baseline laboratory data, and liver stiffness
measurements are summarized in Table 1.
Eleven (38%) patients were asymptomatic with abnormal
liver enzymes discovered on regular blood surveillance.
Table 1 Patient demographics and baseline laboratory values
Parameters Value
Total patients (n) 38
Inadequate follow-up 5
Invalid scans (success \ 60%) 4
Final analysis 29
Sex (male) 23 (79%)
Age (years) 44 (20–69)
HBeAg-positive 16 (55%)
Bilirubin (lmol/L) 34 (10–469)
Alkaline phosphatase (U/L) 114 (56–220)
GGT (U/L) 159 (48–540)
AST (U/L) 524 (208–1,678)
ALT (U/L) 1,464 (594–2,476)
Albumin (g/L) 39 (27–46)
Prothrombin time (s) 12.8 (11.1–24.6)
Platelets (109 L-1) 185 (78–313)
HBV DNA (copies/mL) 100,000,000
(646,020–640,000,000)
Liver stiffness
measurement (kPa)
16.8 (6.9–47.2)
Interquartile ratioa 17% (4–47%)
\10 kPa 7 (24%)
10–20 kPa 10 (35%)
[20 kPa 12 (41%)
Continuous variables expressed as median values
a Interquartile ratio = interquartile range/liver stiffness. Eighty-six
percent of patients had ratio B30%
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Eight (28%) patients presented with jaundice, and ten (35%)
patients presented with non-specific viral symptoms without
jaundice. None of the patients had normal liver stiffness
(\6.0 kPa) at the time of hepatitis flare; the median liver
stiffness was 16.8 kPa (range 6.9–47.2). Twenty-four (83%)
patients were treated with oral nucleoside/nucleotide
analogues.
At 3–6 months follow-up
At 3–6 months, there was a significant decline in liver
stiffness from a median baseline level of 16.8 kPa (range
6.9–47.2) to 7.9 kPa (range 4.6–20.4); (P \ 0.001). Eight
(28%) patients had normalized their liver stiffness results,
as defined by a liver stiffness measurement of \6 kPa,
whereas no patients at baseline had normal liver stiffness
measurement. Patients who normalized their liver stiffness
at 3–6 months had significantly lower liver stiffness at
baseline compared to patients with abnormal liver stiffness
at 3–6 months (9.0 vs. 20.4 kPa, respectively, P = 0.021).
There was no significant difference in the age, and baseline
levels of bilirubin, ALT, platelets, albumin, and pro-
thrombin time, between patients with or without normal
liver stiffness at 3–6 months. Twenty-six (90%) had nor-
malized their ALT, with the remaining three patients only
having minimally elevated ALT of less than twice the
upper limit of normal. The results are summarized in
Table 2.
At 12 months follow-up
At 12 months, the median liver stiffness was 6.9 kPa
(range 3.3–23.6), which was significantly lower when
compared to liver stiffness at 3–6 months after flare
(P = 0.039). Ten patients (34%) had normalized their liver
stiffness after 1 year. All patients had normalized their
ALT at 12 months after initial flare. The results are
summarized in Table 2. Only one patient had HBV DNA
level [105 copies/mL (101,850 copies/mL), and 59% had
undetectable HBV DNA.
Five (17%) patients had the diagnosis of liver cirrhosis
at 12 months, defined by a liver stiffness value of
[10.3 kPa [12]. Baseline factors associated with the
diagnosis of cirrhosis at 12 months included a higher ALP
level (164 vs. 107 U/L, respectively, P = 0.027) and liver
stiffness (40.3 vs. 14.0 kPa, respectively, P = 0.016), and
lower albumin level (35 vs. 40 g/L, respectively,
P \ 0.001), compared to those patients that did not have
cirrhosis. The baseline age, bilirubin, AST, ALT, pro-
thrombin time, platelets, and HBV DNA levels were not
significantly different between these two groups.
The median liver stiffness measurements at baseline,
3–6, and at 12 months are summarized in Fig. 1. The serial
liver stiffness measurements of every individual patient are
shown in Fig. 2. The changes in liver stiffness between
different time points are shown in Fig. 3.
Table 2 Comparison of liver stiffness and liver biochemistry at
baseline, 3–6, and at 12 months
Parameters Baseline 3–6 months 12 months
Total bilirubin 34 (10–469) 12 (4–39) 12 (2–46)
ALT (U/L) 1,464 (594–2,476) 30 (11–66) 21 (13–46)
Albumin (g/L) 39 (27–46) 44 (36–52) 45 (38–49)
Liver stiffness
(kPa)
16.8 (6.9–47.2) 7.9 (4.6–20.4) 6.9 (3.3–23.6)
Continuous variables expressed as median values
 P \ 0.001 comparing liver stiffness value between baseline and
3–6 months
 P = 0.039 comparing liver stiffness value between 3–6 and
12 months
Fig. 1 Median levels of bilirubin, ALT, and liver stiffness at
baseline, 3–6 and 12 months
Fig. 2 Distribution of liver stiffness of all patients at baseline, 3–6,
and at 12 months
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Further follow-up beyond 12 months
Of the 29 patients, 25 were available for repeat liver
stiffness measurement at the time of last follow-up, beyond
the 12 months study period, with a median time of
34 months from the time of flares. There was a further
decline in liver stiffness of 1.0 kPa (P = 0.02) between the
last follow-up time and at 12 months. None of these 25
patients had liver stiffness measurements of [10.3 kPa.
Early decline in liver stiffness
A subgroup of 15 patients (52%) was available at week 4
for early follow-up and had liver stiffness measurements
performed at this visit. There was a significant decline at
4 weeks compared to baseline (8.8 vs. 11.8 kPa, respec-
tively, P = 0.005). At 4 weeks, the median ALT was
103 U/L (range 14–437), compared to the baseline level of
1,532 U/L (range 612–2476). The results are shown in
Fig. 4. Of those patients that had early decline in liver
stiffness, there was no difference in the HBV DNA levels
at 12 months when compared to those patients that did not
have an early decline (144 vs. 60 copies/mL, P = 0.17).
Therefore, early decline in liver stiffness was not predictive
of viral suppression after 1 year.
Correlation of baseline parameters and liver stiffness
The baseline parameters and their correlation are summa-
rized in Table 3. The age, HBeAg status, levels of ALP,
GGT, AST and HBV DNA did not significantly correlate
with liver stiffness. Baseline factors which correlated with
liver stiffness measurements included bilirubin, ALT,
albumin, prothrombin time, and platelet levels (P = 0.010,
P = 0.047, P = 0.010, P \ 0.001 and P = 0.004, respec-
tively). The correlation co-efficient between baseline
parameters and liver stiffness at 3–6 months for bilirubin,
ALT, albumin, prothrombin time, and platelet levels was
0.346 (P = 0.066), 0.220 (P = 0.252), –0.458 (P = 0.013),
0.474 (P = 0.011), and –0.227 (P = 0.245), respectively.
The correlation co-efficient between baseline parameters
and liver stiffness at 12 months for bilirubin, ALT, albumin,
prothrombin time, and platelet levels was 0.324 (P =
0.086), 0.090 (P = 0.642), –0.499 (P = 0.006), 0.321
(P = 0.096), and –0.110 (P = 0.577), respectively. There
were also significant correlations between the liver stiffness
measurement and ALT levels at 3–6 months (correlation
coefficient = 0.449, P = 0.014) and at 12 months (corre-
lation coefficient = 0.458, P = 0.016).
There was no significant difference in baseline liver
stiffness between HBeAg-positive and HBeAg-negative
patients (16.8 vs. 16.4 kPa, respectively, P = 0.942). After
6 months, there was also no significant difference in liver
stiffness between HBeAg-positive and HBeAg-negative
Fig. 3 Median reduction in liver stiffness between baseline and 3–6,
and between 3–6 and 12 months
Fig. 4 Median liver stiffness at baseline and at 4 weeks (subgroup
analysis of 15 patients)
Table 3 Correlation of baseline parameters with liver stiffness
Parameters Correlation coefficienta P value
Age –0.221 0.249
HBeAg status 0.310 0.102
Bilirubin 0.470 0.010
Alkaline phosphatase 0.137 0.478
GGT –0.335 0.110
AST 0.353 0.060
ALT 0.371 0.047
Albumin –0.471 0.010
Prothrombin time 0.687 \0.001
Platelet –0.532 0.004
HBV DNA 0.310 0.102
a Spearman’s correlation coefficient
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patients (7.3 vs. 9.6 kPa, respectively, P = 0.178). There
was also no significant correlation with baseline HBV
DNA with liver stiffness at baseline and at 6 months after
flares (P = 0.102 and P = 0.272, respectively).
ALT flare and liver stiffness
The levels of ALT were stratified into groups above 1,000,
1,500, and above 2,000 U/L. There was no difference in
liver stiffness between patients with ALT [ 1,000 U/L and
in those with ALT \ 1,000 U/L (20.4 vs. 16.3 kPa,
respectively, P = 0.40), and in patients with
ALT [ 1,500 U/L compared with ALT \ 1,500 U/L (23.9
vs. 15.8 kPa, respectively, P = 0.201). There was a sig-
nificant difference in patients with ALT [ 2,000 U/L
compared with those with ALT \2,000 U/L (34.3 vs.
14.4 kPa, respectively, P = 0.022).
Antiviral therapy
Twenty-four (83%) patients received nucleoside/nucleotide
analogues with lamivudine (4 patients), adefovir (2
patients), or entecavir (18 patients). After 3 months, there
was no significant difference in median liver stiffness
reduction in patients who received antiviral therapy and
those that did not (7.2 vs. 12.4 kPa, respectively,
P = 0.845).
Liver histology during flare
Five patients underwent liver biopsy during their inpatient
admission at the time of hepatitis B flare. Two were from
this study population, and three additional patients were
admitted outside the recruitment time. The results are
summarized in Table 4. The liver stiffness score was much
higher than the expected value for the stage of fibrosis
observed on histology.
Discussion
Recently, transient elastography has become available as a
new method in the non-invasive assessment of liver
fibrosis. Although earlier studies had been performed on
Caucasian patients with chronic hepatitis C, more recent
studies have shown transient elastography to be similar in
accuracy for Asian patients and in patients with chronic
hepatitis B [13–17]. Initial studies have shown that liver
stiffness measurement with transient elastography corre-
lated well with underlying liver fibrosis, with good diag-
nostic performance [1–4]. Most of these studies have been
performed on patients with chronic hepatitis C, with less
available data on chronic hepatitis B. Even less data are
available with regard to liver stiffness measurement during
the time of hepatitis flare.
A recent study performed by Arena et al. [8] of 18
patients with acute viral hepatitis [hepatitis A (n = 7), B
(n = 8), and C (n = 3)] has shown a significant correlation
between liver stiffness and serum aminotransferase levels,
concluding that liver stiffness measurement is not reliable
in the context of acute hepatitis. In that particular study, the
timing of liver stiffness measurements was performed with
regard to the defined ALT levels after an episode of flare,
namely at the time when ALT halved, and finally at the
time when ALT was reduced to \2 9 ULN. In another
study performed by Sagir et al. [18] of 20 patients with
hepatitis flares [hepatitis A (n = 1), hepatitis B (n = 8),
toxic (n = 8), and autoimmune hepatitis (n = 3)], liver
stiffness was found to be elevated in the absence of severe
fibrosis or cirrhosis during the time of flare. The correlation
between ALT levels and the liver stiffness measurement
was done by pooling the measurements from 20 patients.
The longitudinal data on liver stiffness were available in a
limited number of patients. In contrast to these two pre-
vious studies, the current study looks specifically at those
patients with acute severe flare of hepatitis B, followed up
for 1 year, with liver stiffness measurement performed at
specific time points, namely, at the time of the severe
flares, 1, 3–6, and 12 months after these flares.
We identified several significant factors which corre-
lated with liver stiffness during an acute flare, including
higher bilirubin, ALT, and prothrombin time, and lower
albumin and platelet levels. The baseline ALT and
platelet levels, however, were not shown to be correlated
with liver stiffness at 3–6 or at 12 months. By contrast,
the baseline albumin level was shown to be inversely
Table 4 Liver stiffness,
histological activity and stage of
fibrosis during severe flare
a Necroinflammatory and
fibrosis score according to the
modified hepatic activity index
grading and staging system
Patient Sex Age ALT Liver stiffness (kPa) Necroinflammatory
score (max 18)a
Fibrosis score
(max 6)a
1 M 28 629 14.3 4 1
2 M 48 759 6.9 3 2
3 M 21 899 8.8 6 1
4 M 46 1,184 20.4 8 3
5 M 24 673 34.3 5 1
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correlated to liver stiffness at baseline, after 3–6, and at
12 months. There was a trend for correlation with base-
line bilirubin level and prothrombin time with liver
stiffness at 12 months. This suggests that baseline
parameters such as bilirubin, prothrombin time, and
albumin may indicate underlying pre-existing damage to
the liver already and is more predictive of long-term
outcome rather than the severity of the ALT rise at the
time of hepatitis flare. By stratifying the ALT levels, a
significantly higher liver stiffness measurement was
shown only for patients with ALT higher than 2,000 U/L.
The significance of this remains to be defined.
Most of the decline in liver stiffness after a severe flare
occurs within the first 6 months, with only further minimal
reduction from 6 to 12 months. These results suggest that
after an acute hepatitis B flare, liver stiffness returns close
to its background level by 3–6 months, with further mini-
mal decline over the next 6 months. This is in keeping with
a larger population study of 1,315 CHB patients, whereby
the median liver stiffness was found to be 6.7 kPa, which is
comparable to the value of 6.9 kPa at 12 months after flare
in the present study population [13]. Although the decline
in liver stiffness in our patients may be partly related to
reversal of fibrosis with antiviral therapy, it is likely that
the major cause of the decline was due to decrease in
inflammatory activities. Liver stiffness measurements
should be performed at least 6 months after resolution of
severe flares (e.g. ALT \ 2 9 ULN). If the results remain
unexpectedly high, we would recommend repeating
another scan in a further 6 months time, as we have shown
that there is a further significant decline in liver stiffness
between 3–6 and 12 months. Moreover, in those patients
with a persistently high measurement at 12 months, a
further scan is recommended, as in the current study, these
patients had further decline in their liver stiffness at the
time of last follow-up. This would give a more accurate
assessment of the degree of background severe fibrosis or
cirrhosis.
Whether this can be applied to other causes of severe
acute flares of hepatitis, such as acute alcoholic hepatitis,
autoimmune flares, acute presentation of Wilson’s disease,
drug-related hepatitis, or other viral hepatitis, remains to be
determined. The two previous studies, having shown that
liver stiffness is elevated during acute hepatitis flares from
other causes, including hepatitis A, hepatitis C, toxic
hepatitis, and autoimmune hepatitis, will provide strong
evidence for this [8, 18]. Of note, an increased liver stiff-
ness measurement after an episode of severe flare was not
predictive of the presence of underlying advanced fibrosis
or cirrhosis, as all patients had lowered their liver stiffness
at the time of last follow-up.
Although we have shown that liver stiffness is signifi-
cantly higher during the time of hepatitis flare, the nature of
this elevated liver stiffness remains to be determined.
Whether the higher measurements reflect truly the increase
in fibrosis or reflects the architectural changes associated
with necro-inflammatory activity, such as cellular infiltra-
tion, tissue necrosis, or tissue edema, is currently unknown.
Furthermore, there remains the possibility that the higher
liver stiffness measurements seen during an acute hepatitis
flare may be artefactual, due to higher water content at the
time of severe flares, rather than a true increase in liver
stiffness. There is likely a complex interplay of matrix
metalloproteinases and their inhibitors during the phase of
acute viral hepatitis which may influence liver stiffness at
the time of inflammation [19].
The true nature of the increased liver stiffness during a
hepatitis flare can only be delineated by liver biopsy. We
report five biopsies performed at the time of hepatitis B
flare, showing a higher liver stiffness value than expected
for the stage of fibrosis on histology. In addition, the fact
that liver stiffness was significantly reduced by as early as
1 month in our subgroup analysis, and after 3–6 months
from flares, suggests that the increase in liver stiffness is
not reflective of underlying fibrosis, and more as a result of
inflammation. This is supported by the lack of significant
fibrosis on liver histology in the current study despite
having an elevated liver stiffness value, and also in a
previous study [18].
Further studies are required to determine whether liver
stiffness is affected by moderate inflammatory activity (e.g.
ALT 2–5 times upper limit of normal). In a recently pub-
lished study, increasing liver stiffness correlated well with
even smaller gradients of ALT, including \0.5 9 ULN,
0.5–1 9 ULN, and 1–2 9 ULN [13]. However, because of
the high area under the receiver operating characteristic
curve (AUROC) already achieved with transient elastog-
raphy, such small increments in ALT are unlikely to affect
the accuracy of the test, and smaller increments in liver
enzymes may reflect underlying fibrosis rather than
inflammation.
There were several limitations of the current study. First,
the sample size was small; however, this is because the
overall number of admissions for severe flares of CHB is
relatively small. Despite the small sample size, the study
was able to show significant liver stiffness changes over the
different time points. Second, there were only a limited
number of liver biopsies performed, as this is seldomly
carried out in patients with well-documented evidence of
hepatitis B flares. In addition, over one-third of the patients
admitted for severe flares had elevated prothrombin time,
precluding percutaneous biopsies.
In conclusion, liver stiffness is increased in chronic
hepatitis B patients with severe flares, with return to near
normal levels by 6 months. We recommend measuring
liver stiffness to document liver fibrosis or cirrhosis in
Hepatol Int (2010) 4:716–722 721
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patients having severe hepatitis B flares should be post-
poned to at least 6 months after flare.
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